Form 8-K Phathom Pharmaceuticals, For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
August 8, 2024 4:17 PM EDTGoldman Sachs analyst Paul Choi raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $12.00 (from $10.00) while maintaining a Neutral rating.
The analyst comments "Topline beat for Voquezna reflects commercial progress though sales remain nominal. PHAT announced its 2Q24 financial results this... More
